2160
GNI Group Ltd.
ジーエヌアイグループ
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- IFRS
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Dec 2021
12,690
Dec 2022
17,419
Dec 2023
26,011
Dec 2024
23,612
Dec 2025
26,840
Operating profit(million JPY)
Dec 2021
1,625
Dec 2022
1,378
Dec 2023
13,109
Dec 2024
1,402
Dec 2025
-3,471
Operating profit margin(%)
Dec 2021
12.8
Dec 2022
7.91
Dec 2023
50.4
Dec 2024
5.94
Dec 2025
-12.93
Profit before tax(million JPY)
Dec 2021
1,107
Dec 2022
768
Dec 2023
12,613
Dec 2024
238
Dec 2025
-4,634
Profit(million JPY)
Dec 2021
1,066
Dec 2022
389
Dec 2023
8,094
Dec 2024
1,098
Dec 2025
-4,244
Total assets(million JPY)
Dec 2021
30,297
Dec 2022
33,907
Dec 2023
62,394
Dec 2024
71,943
Dec 2025
83,791
Cash and cash equivalents(million JPY)
Dec 2021
14,352
Dec 2022
11,049
Dec 2023
21,633
Dec 2024
10,115
Dec 2025
21,101
Cash flows from operating activities(million JPY)
Dec 2021
552
Dec 2022
393
Dec 2023
6,549
Dec 2024
-3,164
Dec 2025
-2,408
Cash flows from investing activities(million JPY)
Dec 2021
-261
Dec 2022
-4,116
Dec 2023
-6,843
Dec 2024
-10,361
Dec 2025
-536
Cash flows from financing activities(million JPY)
Dec 2021
2,853
Dec 2022
-646
Dec 2023
10,687
Dec 2024
694
Dec 2025
13,738
Return on equity(%)
Dec 2021
7.1
Dec 2022
2
Dec 2023
29.6
Dec 2024
3.1
Dec 2025
-9.8
Equity ratio(%)
Dec 2021
62.3
Dec 2022
61.8
Dec 2023
54.2
Dec 2024
50.7
Dec 2025
60.1
Earnings per share(JPY per share)
Dec 2021
22.72
Dec 2022
8.19
Dec 2023
169.5
Dec 2024
21.96
Dec 2025
-80.9
Net assets per share(JPY per share)
Dec 2021
397.38
Dec 2022
441.59
Dec 2023
678.01
Dec 2024
726.67
Dec 2025
903.93
Dividend per share(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Payout ratio(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.